This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
It appears our friends in Europe have decided that an 6 to 8 percent improvements in lung function (2 clinical trials) in over 600 CF patients over a 12 months is not an sufficient improvement in FEV1 to justify approving the dry powder for marketing approval in Europe. You have to wonder why...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.